



To,

May 29, 2026

National Stock Exchange of India Ltd.

Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

ISIN: INE0PLQ01011

Sub: Outcome of the Board Meeting held on Friday, 29th May, 2026

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 29, 2026, inter-alia considered and approved the followings:

1. Audited Standalone and Consolidated Financial Results for half year and year ended March 31, 2026. Pursuant to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the following:
 - (a) Statement of Audited Standalone and Consolidated Financial Results for the half year and year ended March 31, 2026.
 - (b) Audit Reports, issued by Statutory Auditors of the Company, on the Audited Financial Results of the Company for the half year and year ended March 31, 2026.
 - (c) A confirmation pursuant to regulation 33(3) (d) of SEBI (LODR) Regulations 2015 from the CFO of the Company, declaring that the statutory auditors have expressed an unmodified audit opinion in respect of financial results.
2. Appointment of M/s. R P V & Company (FRN: 0134844W), Chartered Accountants as the Internal Auditor of the Company for the financial year 2026-27.

Maitreya Medicare Limited

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.
Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyamedicare@gmail.com
CIN : L24290GJ2019PLC107298



3. Re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Practicing Company Secretaries (Firm Registration No. L2025GJ019100 / Peer Review Certificate No. 6787/2025) as Secretarial Auditor of the Company for the financial year 2026-27.
4. Took note of the resignation of Dr. Pranav Rohitbhai Thaker (DIN: 07602708) from the position of Whole-time Director of the Company w.e.f. the closure of business hours on 25th May, 2026.
5. Redemption of 90,000 6% Non-Convertible Cumulative Redeemable Preference Shares

The particulars / details with respect to re-appointment of Secretarial Auditor and Appointment Internal Auditor of the Company as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed as **Annexure A**.

The aforesaid Board Meeting commenced at 03:00 p.m. (IST) and concluded at 04:20 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

Kashish Surana
Company Secretary & Compliance Officer
ACS- 76674

Encl. as above

Maitreya Medicare Limited

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.
Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyamedicare@gmail.com
CIN : L24290GJ2019PLC107298



Annexure-A

Sr. No.	Particulars	M/s. JDM and Associates LLP
1	Reason for change viz. appointment, reappointment, resignation, removal, death of otherwise	Re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: L2025GJ019100), as Secretarial Auditors of the Company.
2	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/reappointment	The Board at its meeting held on May 29, 2026, approved the re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP as Secretarial Auditors, for the financial year 2026-27.
3	Term of Appointment /re-appointment	1 year
4	Brief Profile	JDM and Associates LLP (Firm Registration No. L2025GJ019100) is Peer reviewed firm and is an integrated corporate service firm focused on Corporate Laws & Secretarial Compliances, Due Diligence, Certifications, XBRL filing, Startup Consultancy Services, Regulatory Authority Services, Secretarial Audits, Corporate Governance Audit, IPO Pre-Post Due-diligence services and related matters.
5	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable
6	Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/ 2018-19 and NSE ref. no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable

Sr. No.	Particulars	M/s. R P V & Company
1	Reason for change viz. appointment, reappointment, resignation, removal, death of otherwise	To comply with the provisions of the Companies Act, 2013 & SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, upon recommendation of Audit Committee, the



		Board of Directors at its meeting held on 29 th May, 2026, Appointed M/s. R P V & Company as Internal Auditor of the Company, for a period of 1 (One) year.
2	Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/ reappointment	Appointment of M/s. R P V & Company as Internal Auditor of the Company, shall be for the financial year 2026-27.
3	Term of Appointment re-appointment	1 Year
3	Brief Profile (in case of appointment)	M/s. R P V & Company, a firm of Chartered Accountant being the Internal Auditor of the Company is a good leader in providing expert and professional services with due care of professional ethics.
4	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable

Maitreya Medicare Limited

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.
Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyamedicare@gmail.com
CIN : L24290GJ2019PLC107298



To,

May 29, 2026

National Stock Exchange of India Ltd.

Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulation, 2016

I, Narendra Singh Tanwar, Chief Financial Officer of Maitreya Medicare Limited, having its Registered Office at Nr Someshwara Char Rasta, Um Road, Surat, Gujarat, India, 395007 hereby declare that the Statutory Auditors of the Company M/s. Saherwala & Co. have issued an Audit Report with unmodified opinion on the Annual Audited Financial Result of the Company (Standalone & Consolidation) for the half year and year ended on 31st March, 2026.

The Disclosure is given in compliance to Regulation 33(3)(d) of SEBI (LODR) Regulation, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide circular No CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kind take this declaration on your record.

Your Sincerely,

Maitreya Medicare Limited

Narendra Singh Tanwar
Managing Director & CFO
DIN: 08459007

Maitreya Medicare Limited

Address : Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat - 395007.
Ph. : 0261-2299000 | Reception : +91 82382 29900 | Email : maitreyamedicare@gmail.com
CIN : L24290GJ2019PLC107298



Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:

ACURA
& Affiliates

Approved CA Network

Presence in :-
Bengaluru, Delhi, Mumbai, Chennai,
Kolkata, Pune, Hyderabad, Patna,
Mysuru, Khagaria, Belgavi, Tirupur,
Jaipur, Kurnool, **Surat**,
Ahmedabad, Vellore & Burdwan

INDEPENDENT AUDITOR'S REPORT

To the Members of **MAITREYA MEDICARE LIMITED**


Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

1. We have audited the accompanying Standalone financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited*), which comprise the balance sheet as at 31st March 2026, and the statement of profit and loss, statement of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

2. The management and Board of Directors of the Company are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the act') with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with rule 7 of Companies (Accounts) Rules, 2014. This responsibility includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of



[Signature]

1/98, Golandaz Street, Nanpura, Surat - 395 001.

Ph. : (0261) 2472398, 2470084 Mob. : 93273 33227 E-mail : saherwalaca@yahoo.co.in, contact@saherwala.com
www.saherwala.com


5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion


6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2026, its profit/loss and its cash flows for the period ended on that date.

Report on Other Legal and Regulatory Requirements

7. As required by the Companies (Auditor's Report) Order, 2020 issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the "Annexure A" a statement on the matters Specified in paragraphs 3 and 4 of the Order report as per this order.
8. As required by section 143(3) of the Act, we further report that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;



- d) in our opinion, the aforesaid Standalone financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.
- e) on the basis of written representations received from the directors as on March 31, 2026, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:
- i. The Company does not have any legal pending court litigations which would impact its financial position; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 31.24 to the Balance Sheet)
 - ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;



- iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.
- h) The company, has used such accounting software for maintaining its books of account which:
- i. Has a built-in Feature of recording audit trail (edit log) facility and
 - ii. The audit trail has operated throughout the year for all transactions recorded in the software and
 - iii. The audit trail feature has not been tampered with.
 - iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

PLACE: SURAT
DATE: 29.05.2026



FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

A handwritten signature in black ink, appearing to read "E. O. Saherwala".

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386

UDIN: 26 122386 YLR STC 9026

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107296

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Particulars	Half year ended			For the year ended	For the year ended
	March 31, 2026	September 30, 2025	March 31, 2025	March 31, 2026	March 31, 2025
	Audited	Unaudited	Audited	Audited	Audited
I Revenue from operations	2,094.32	2,327.80	2,223.34	4,422.12	4,441.32
II Other income	59.12	14.09	29.70	73.21	43.98
III Total Revenue (I + II)	2,153.44	2,341.89	2,253.04	4,495.33	4,485.30
IV Expenses:					
(a) Cost of Raw Material Consumed	259.46	213.65	127.73	473.11	286.80
(b) Purchase of Stock-in-Trade	215.64	257.92	325.66	473.56	586.29
(c) Changes in inventories of stock-in-trade	0.71	-0.15	-1.65	0.56	(1.05)
(d) Employee benefits expense	258.71	250.46	278.32	509.17	521.88
(e) Finance costs	91.18	36.74	37.09	127.92	75.44
(f) Depreciation and amortization expense	66.62	71.47	71.14	138.09	134.59
(g) Other expenses	1,405.47	1,489.76	1,278.01	2,895.23	2,559.09
Total Expenses	2,297.79	2,319.85	2,116.30	4,617.64	4,163.06
V Profit before prior-period items and tax (III - IV)	(144.35)	22.04	136.74	(122.31)	322.25
VI Prior-Period Items	11.79			11.79	
VII Profit before tax (V - VI)	(156.14)	22.04	136.74	(134.10)	322.25
VIII Tax expense:					
(1) Current tax expense	-5.73	5.73	30.99	-	80.75
(2) Deferred tax expense/(credit)	3.13	1.58	-	4.71	1.13
(3) Short/(Excess) provision of tax for earlier years	-6.34		50.42	(6.34)	50.42
Dividend on Preference Shares	(8.94)	7.31	81.41	(1.63)	132.29
IX Profit from continuing operations (VII-VIII)	(147.20)	14.73	85.21	(132.47)	189.96
X Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	677.60	677.60	677.60	677.60
XI Reserves excluding revaluation reserves as per balance sheet of previous accounting year					
XII Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each					
(Pre-bonus)					
- Basic					
- Diluted	(2.17)	0.22	0.82	(1.95)	2.80
(Post-bonus)					
- Basic					
- Diluted					

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

S. C. Saherwala
(ESMAYEEL O. SAHERWALA)
Chartered Accountant

M. NO. 122386
29th May 2026, Surat.

UDIN: 26122386 YLR 27C 9026



NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

Narendra Tanwar

VIMAL PATEL
DIN - 08458999
Wholtime Director

Vimal Patel

Kashish Surana
M.NO - A76674
Company Secretary
Kashish Surana

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED BALANCE SHEET AS ON 31st March 2026


CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders' Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	186593	199841
c) Money received against share warrants			
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	3	216977	19594
b) Deferred tax liability (Net)	4	7878	6953
c) Other long term Liabilities			
d) Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	5	11786	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and	6	4696	2876
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.	6	28045	24937
c) Other current Liabilities			
d) Short term Provisions.			
Total	8	632902	444136
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment			
(ii) Intangible Assets	9	329784	118212
b) Non Current Investments			
c) Deferred tax asset (net)	10	1149	1445
d) Long term loans and advances	11	75730	75830
e) Other Non current assets			
(2) Current assets	12	54912	52238
a) Current Investments	13	10859	12722
b) Inventories	14	522	422
c) Trade receivables	15	7740	4798
d) Cash & Cash equivalents	16	116155	151850
e) Short-term loans and advances	17	28937	19090
f) Other current assets	18	3794	5019
Total			
Total	8	632902	444136

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

E. O. Saherwala
(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN : 26123864LR57



For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN - 08458999
Wholtime Director

Narendra
Kashish Surana
M.No. A76674
Company Secretary

Vimal Patel
Surana

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED CASH FLOW STATEMENT
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS	As at 31st March 2026		As at 31st March 2025	
A. Cash Flow from Operating Activities:				
Profit Before exceptional and extraordinary items and tax		-12232		32224
Adjustments for :				
Depreciation	13809		13459	
Interest Income	-2387		-695	
Gratuity			1677	
Interest & Finance Charges Paid	12792		7544	
Profit on sale of investment			-225	
Prior Period Adjustment - gst	-725			
Reversal of Previous Year Income Tax	634			
Profit on sale of Fixed Assets	-20			
		24104		21761
Operating Profit before Working Capital Changes		11872		53985
Adjustments for :				
Increase / Decrease in Inventories	-2942		-113	
Increase / Decrease in Short-term loans and advances	1225		-3478	
Increase / Decrease in Trade Receivables	35695		-21142	
Increase / Decrease in Trade Payables	4928		4932	
Increase / Decrease in other Current Assets	-811		3312	
Increase / Decrease in Other Non Current Assets	1864		4174	
Increase/Decrease in Provision	-8075		-3918	
Increase/Decrease in short term Borrowings	-3957		2143	
Increase/Decrease in other current liabilities	16211	44137	25559	10849
Cash Generated from Operations		56009		64834
Direct Taxes Paid (Net)	1203.17	1203	14547	14547
Net Cash inflow in Operating Activities	Total A	54806	Total A	50287
B. Cash Flow from Investing Activities:				
Purchases of Fixed assets	-225197		-23741	
Purchase of Investment	-100		-44206	
Capital Government Grant of Fixed Assets				
Loans given to Associates and Subsidiaries	-1471		-9073	
Repayment of Loans given to Associates and Subsidiaries				
Interest Income	2387		695	
Gain on Sale of Fixed Assets				
Sale of Fixed Assets	131			
Gain on Sale of Investment				



Sale of Investment					
Net Cash used in Investing Activities	Total B	100	-224150	4300	-72026
C. Cash Flow from Financing Activities:			-224150	Total B	-72026
Issue of Equity Capital					
Share Premium					
Dividend					
Issue of Preference Shares					
Redemption of Preference shares		-5400		-800	
Repayment of Borrowing		197383		-7441	
Interest & Finance Charges Paid		-12792	179191	-7544	-15785
Net Cash from Financing Activities	Total C		179191	Total C	-15785
Net Increase/(decrease) in cash and cash equivalents (A+B+C)	Total (A+B+C)		9847	Total (A+B+C)	-37524
Opening Cash and Cash equivalents			19090		56614
Closing Cash and Cash equivalents			28937		19090


Notes:

- (i) Figures in brackets represent outflow.
(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013
(iii) Cash and Cash Equivalents represent cash and bank balances.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

E. O. Saherwala

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. No. 122386
29th May 2026, Surat.
UDIN : 28122386 YLRSTC 9026



For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Narendra

Vimal Patel

Kashish Surana
M.No. A76674
Company Secretary
Kashish Surana

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited standalone financial results

- 1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 29, 2026.
- 2 The Results for the half year and year ended March 31, 2026 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 4 The figures for the half year ended September 30, 2025 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 5 The figures for the half-year ended March 31, 2026 are unaudited published figures in respect of the half-year ended September 30, 2025 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The figures for the half-year ended March 31, 2026 are balancing figure between unaudited figures in respect of the half year ended september 30, 2025 limited reviewed by the statutory auditors and audited figures for the financial year ended March 31, 2026 .The comparative results for the year ended March 31, 2026 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2026 are audited published figures in respect of the year ended March 31, 2026 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 8 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.



Maitreya Medicare Limited
 (Formerly known as "Maitreya Medicare Private Limited")
 CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited standalone financial results

9 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till MARCH 31, 2026 (₹ in Thousands)	Amount unutilised till MARCH 31, 2026 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		148,912.00	148,512.00	400.00	

As Per Our Report of Even Dated Annexed
 Saherwala & Co.
 FRN 108969W

(Signature)
 (ESMAYEEL O. SAHERWALA)
 Chartered Accountant

M. NO. 122386
 29nd May 2026, Surat.
 UDIN: 26 122386 YLR STC 9026



NARENDRA TANWAR
 DIN - 0008459007
 MD AND CFO

(Signature)

Kashish Surana

M.No. A76674

Company Secretary

(Signature)

VIMAL PATEL
 DIN- 08458999
 Wholetime Director

(Signature)



Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of

ACURA
& Affiliates

Approved CA Network

Presence in :-
Bengaluru, Delhi, Mumbai, Chennai,
Kolkata, Pune, Hyderabad, Patna,
Mysuru, Khagaria, Belgavi, Tirupur,
Jaipur, Kurnool, **Surat**,
Ahmedabad, Vellore & Burdwan

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

1. We have audited the financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited*) and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), which comprise the Consolidated balance sheet as at 31st March 2026, and the Consolidated statement of profit and loss, the Consolidated Statement of Changes in Equity, Consolidated statement of cash flows for the period then ended, and notes to the Consolidated financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

2. The Holding Company's Board of Directors are responsible for the preparation of these consolidated financial statements in terms of the requirements of the Companies Act, ('the act') that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are



reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid;

Auditor's Responsibility

3. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

4. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the consolidated financial statements, that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness



of the accounting estimates made by the Company's management and Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March 2026, and their consolidated ~~profit~~/loss and their consolidated cash flows for the period ended on that date.
7. As described in the notes no 1.13 to the financial statements statutory auditor of WOS Maitrya Lifescience Private Limited has qualified his report that, the MLPL Company has not complied with the requirements of Section 55 of the Companies Act, 2013 and the accounting principles generally accepted in India in the preparation and presentation of these financial statements, resulting in material misstatements whose effects are material but not pervasive to the financial statements. These matters collectively form the basis for our Qualified Opinion in accordance with SA 705 (Revised).

Report on Other Legal and Regulatory Requirements

7. According to the information and explanations given to us, and based on the reports, issued by the auditors of the subsidiaries included in the consolidated financial statements of the Company, to which reporting on matters specified in paragraph 3 and 4 of the Order is applicable, provided to us by the Management of the Company and based on the identification of matters of qualifications or adverse remarks in their Companies (Auditor's Report) Order, 2020 reports by




the respective component auditors and provided to us, we report that the auditors of such companies have not reported any qualifications or adverse remarks in their CARO reports.

8. As required by section 143(3) of the Act, we further report that:
- a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) the Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
 - d) in our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.
 - e) on the basis of written representations received from the directors of the Holding Company as on 31st March, 2026 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies, incorporated in India, none of the directors of the Group companies, incorporated in India is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
 - g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:



- i. The Company does not have any legal pending court litigations which would impact its financial position of the Group; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 32.24 to the Balance Sheet)
 - ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;
 - iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.
- h) The company, has used such accounting software for maintaining its books of account which:
- i. Has a built-in Feature of recording audit trail (edit log) facility and
 - ii. The audit trail has operated throughout the year for all transactions recorded in the software and
 - iii. The audit trail feature has not been tampered with.
 - iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

PLACE: SURAT
DATE: 29/05/2026



FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

Esmayeel O. Saherwala

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386

UDIN: 26122386UPB0FR5710

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

(₹ in Lakhs)

Particulars	Half Year ended		For the year ended		
	March 31, 2026	September 30, 2025	March 31, 2025	March 31, 2025	
	Audited	Unaudited	Audited	Audited	
I Revenue from operations	2,115.06	2,369.93	2,229.92	4,484.99	4,666.20
II Other income	75.73	22.98	38.23	98.71	57.22
III Total Revenue (I + II)	2,190.79	2,392.91	2,268.15	4,583.70	4,723.42
IV Expenses:					
(a) Cost of Raw Material Consumed	259.46	213.65	128.11	473.11	287.17
(b) Purchase of Stock-in-Trade	220.54	257.92	329.49	478.46	591.39
(c) Changes in inventories of stock-in-trade	0.71	4.14	-7.14	4.85	(2.48)
(d) Employee benefits expense	285.92	270.57	329.31	556.49	612.78
(e) Finance costs	105.51	42.89	35.11	148.40	80.20
(f) Depreciation and amortization expense	73.14	79.06	83.54	152.20	149.64
(g) Other expenses	1,485.90	1,519.61	1,280.37	3,005.51	2,689.12
Total Expenses	2,431.18	2,387.84	2,178.79	4,819.02	4,407.83
V Profit before prior-period items and tax (III - IV)	(240.39)	5.07	89.36	(235.32)	315.59
VI Prior-Period Items					
	11.79			11.79	
VII Profit before tax (V - VI)	(252.18)	5.07	89.36	(247.11)	315.59
VIII Tax expense:					
(1) Current tax expense	-7.29	7.29	24.89	-	82.72
(2) Deferred tax expense/(credit)	4.37	1.39	-0.52	5.76	0.63
(3) Short/(Excess) provision of tax for earlier years	-6.34	-	50.42	(6.34)	50.42
	(9.26)	8.68	74.79	(0.58)	133.78
IX Profit from continuing operations (VII-VIII)	(241.92)	(1.61)	14.57	(246.53)	181.81
X Minority Interest					
XI Profit attributable to owners of the equity (IX-X)	(241.92)	(1.61)	14.57	(246.53)	181.81
XII Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.6	677.60	677.60	677.60	677.60
XIII Reserves excluding revaluation reserves as per balance sheet of previous accounting year					
XIV Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each					
(Pre-bonus)					
- Basic	-3.59	-0.05	0.22	-3.64	2.68
- Diluted					
(Post-bonus)					
- Basic					
- Diluted					

As Per Our Report of Even Dated Annexed

Saherwala & Co.
FRN 108969W

S. O. Saherwala
(ESMAYEEL O. SAHERWALA)
Chartered Accountant

M. NO. 122386
29th May 2026, Surat.

UDIN: 26122386UPBQFF



NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

Narendra

VIMAL PATEL
DIN- 08458999

Wholetime Director

Vimal Patel

Kashish Surana
M.No- A76674
Company Secretary
Kashish Surana

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
CONSOLIDATED AUDITED BALANCE SHEET AS ON 31st March 2026
CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000)

Particulars	Note No.	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
		As at 31st March 2026	As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders' Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	174775	199428
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	7480	8227
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	4	219396	36348
b) Deferred tax liability (Net)	5	8064	7034
c) Other long term Liabilities			
d) Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	6	11786	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises;			3295
and small enterprises.	7		
(B) total outstanding dues of creditors other than micro enterprises		40110	28867
and small enterprises.			
c) Other current Liabilities	8	107260	51305
d) Short term Provisions	9		8272
Total		684395	479943
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Gross Block		490270	219621
(ii) Depreciation	10	82128	67024
(iii) Net Block		408142	152597
b) Non Current Investments	11	10	10
c) Deferred tax asset (net)			
d) Long term loans and advances	12	29622	30489
e) Other Non current assets	13	12946	18442
(2) Current assets			
a) Current Investments	14	522	422
b) Inventories	15	8436	5923
c) Trade receivables	16	110212	149565
d) Cash & Cash equivalents	17	86696	79163
e) Short-term loans and advances	18	23429	39789
f) Other current assets	19	4379	3542
Total		684395	479943

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W


(Signature)
(ESMAYEEL O. SAHERWALA)

Chartered Accountant

M. NO. 122386

29th May 2026, Surat.

UDIN : 26122386UPBQFR5710



For MAITREYA MEDICARE LIMITED

NARENDRA TANIWAR

DIN - 0008459007

MD AND CFO

VIMAL PATEL

DIN- 08458999

Wholetime Director

(Signature)
Kashish Surani

M.NO - A76674

Company Secretary

(Signature)

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Audited Cash Flow Statement for the year ended 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS	CONSOLIDATED AMOUNT	CONSOLIDATED AMOUNT
	As at 31st March 2026	As at 31st March 2025
A. Cash Flow from Operating Activities:		
Net Profit before tax	-23533	32102
Adjustments for:		
Depreciation	15220	14421
Interest Income	-4864	2154
Interest & Finance Charges Paid	13630	7984
Gratuity		1677
Profit on sale of Investment		225
Prior Period Adjustment - gst	-725	
Reversal of Previous Year Income Tax	634	
Profit on sale of Fixed Assets	-20	
Sub Total	23876	22153
Operating Profit before Working Capital Changes	343	54255
Adjustments for:		
Increase / Decrease in Inventories	-2513	147
Increase / Decrease in Short-term loans and advances	1225	-3478
Increase / Decrease in Trade Receivables	44129	-18444
Increase / Decrease in Trade Payables	-785	6571
Increase / Decrease in Other Current Assets	15009	-619
Increase / Decrease in Other Non Current Assets	342	-4174
Increase / Decrease in Long-term loans and advances	-19246	145
Increase/Decrease in Provision	-8300	-3918
Increase/Decrease in short term liabilities	-3957	2143
Increase/Decrease in Current Liability	59438	24289
Sub Total	85344	11000
Cash Generated from Operations	85688	65284
Direct Taxes Paid (Net)	1203	14695
Net Cash Inflow in Operating Activities Total A	84484	50568
B. Cash Flow from Investing Activities:		
Purchases of Property, Plant and Equipment	-272483	-23813
Purchase of Investment	-100	-44656
Depreciation reversed back on sale of fixed assets		
Capital Government Grant of Property, Plant and Equipment		
Loans given to Associates and Subsidiaries		
Loans given to Others	-1471	-9073
Loans received from Holding company		
Interest Income	4864	-2621
Sale of Fixed Assets	1738	2154
Sale of Investment	100	4300
Sub Total	-267351	-73709
Net Cash used in Investing Activities Total B	-267351	-73709
C. Cash Flow from Financing Activities:		
Issue of Equity Capital	3900	
Share application Money	-100	51600
Share Premium		
Dividend		
Proceed of Borrowing	12895	4783
Issue of Preference Shares		
Redemption of Preference shares	-10047	-2000
Repayment of Borrowing	197383	-9665
Interest & Finance Charges Paid	-13630	7984
Sub Total	190401	35735
Net Cash from Financing Activities Total C	190401	35735
Net Increase / (decrease) in cash and cash equivalents (A+B+C)	7534	13594
Opening Cash and Cash equivalents	79163	65569
Closing Cash and Cash equivalents	86696	79163


Notes:
(i) Figures in brackets represent outflow. -108.17

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act, 2013

(iii) Cash and Cash Equivalents comprise of bank balances.

As Per Our Report of Even Date Annexed
Saherwala & Co.
FRN 108969W

S. O. Saherwala
(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. No. 122386
29th May 2026, Surat.
UDIN: 26122386UPBAFR5710



Kashish Surana
M.No - A76674
Company Secretary
Kashish Surana

KARENDRA TANWAR
DIN - 0008459007
MD AND CFO
Karendera

For MAITREYA MEDICARE LIMITED

VIMAL PATEL
DIN- 08458999
Wholtime Director
Vimal Patel

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited consolidated financial results

- 1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 29, 2026.
- 2 The Results for the half year and year ended March 31, 2026 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The results includes results of 1 wholly owned subsidiaries - Maitreya Lifescience Private Limited and 2 subsidiary - Maitreya Hospital Private Limited and Tulip Agility Private Limited.
- 4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 5 The figures for the half year ended September 30, 2025 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 6 The figures for the half-year ended March 31, 2026 are balancing figure between unaudited figures in respect of the half year ended september 30, 2025 limited reviewed by the statutory auditors and audited figures for the financial year ended March 31, 2026 .The figures for the half-year ended September 30, 2025 are unaudited published figures in respect of the half-year ended September 30, 2025 limited reviewed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 7 The comparative results for the year ended March 31, 2026 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2026 are audited published figures in respect of the year ended March 31, 2026 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.
- 8 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.
- 9 During the preceding year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.



Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited consolidated financial results

10 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till MARCH 31, 2026 (₹ in Thousands)	Amount unutilised till MARCH 31, 2026 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		148,912.00	148,512.00	400.00	

As Per Our Report of Even Dated Annexed

Saherwala & Co.
FRN 108969W

E. O. Saherwala

(ESMAYEEL O. SAHERWALA)

Chartered Accountant

M. NO. 122386

29th May 2026, Surat.

UDIN: 26122386UPB&FRS710



NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

Narendra Tanwar

VIMAL PATEL
DIN- 08458999

Wholetime Director

Vimal Patel

Kashish Surana

M. NO - A76674

Company Secretary

Kashish Surana